<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PAG/Cbp is a transmembrane adaptor protein involved in proximal immune signaling </plain></SENT>
<SENT sid="1" pm="."><plain>It is expressed in reactive germinal centers (GC) of secondary lymphatic follicles and related malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We studied PAG/Cbp expression in GC-like and non-GC-like diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) subtypes </plain></SENT>
<SENT sid="3" pm="."><plain>Seventy-three cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> identified among 155 malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were classified as GC-like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (CD10+ or CD10-, bcl-6+, and MUM1-) and non-GC-like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (CD10-, MUM1+ or CD10-, bcl-6+, MUM1+) </plain></SENT>
<SENT sid="4" pm="."><plain>PAG/Cbp was detected by monoclonal antibody MEM-255 following routine immunohistochemical procedures </plain></SENT>
<SENT sid="5" pm="."><plain>Thirty-five of 40 GC-like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> (88%) and 20 of 33 non-GC-like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> cases (61%) expressed PAG/Cbp </plain></SENT>
<SENT sid="6" pm="."><plain>Four of 12 bcl-6-negative non-GC-like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> cases (33%) were PAG/Cbp positive, and only 4 of 20 bcl-6-positive non-GC-like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> cases (25%) were PAG/CBP negative </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 37 FL and <z:hpo ids='HP_0000001'>all</z:hpo> 5 Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) expressed PAG/Cbp, whereas <z:hpo ids='HP_0000001'>all</z:hpo> 6 mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) and 4 of 5 <z:hpo ids='HP_0005550'>chronic lymphocytic leukemias</z:hpo> (<z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e>) were PAG/Cbp negative </plain></SENT>
<SENT sid="8" pm="."><plain>PAG/Cbp is a reliable GC marker </plain></SENT>
<SENT sid="9" pm="."><plain>Its expression correlates with GC-like DLBC phenotype in a significant majority of cases </plain></SENT>
<SENT sid="10" pm="."><plain>It is typically absent in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL </plain></SENT>
</text></document>